Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
PLoS One ; 13(1): e0190820, 2018.
Article in English | MEDLINE | ID: mdl-29304096

ABSTRACT

Hyperphosphatemia and vascular calcification are frequent complications of chronic renal failure and bone morphogenetic protein 7 (BMP7) has been shown to protect against development of vascular calcification in uremia. The present investigation examined the potential reversibility of established uremic vascular calcification by treatment of uremic rats with BMP7. A control model of isogenic transplantation of a calcified aorta from uremic rats into healthy littermates examined whether normalization of the uremic environment reversed vascular calcification. Uremia and vascular calcification were induced in rats by 5/6 nephrectomy, high phosphate diet and alfacalcidol treatment. After 14 weeks severe vascular calcification was present and rats were allocated to BMP7, vehicle or aorta transplantation. BMP7 treatment caused a significant decrease of plasma phosphate to 1.56 ± 0.17 mmol/L vs 2.06 ± 0.34 mmol/L in the vehicle group even in the setting of uremia and high phosphate diet. Uremia and alfacalcidol resulted in an increase in aortic expression of genes related to fibrosis, osteogenic transformation and extracellular matrix calcification, and the BMP7 treatment resulted in a decrease in the expression of profibrotic genes. The total Ca-content of the aorta was however unchanged both in the abdominal aorta: 1.9 ± 0.6 µg/mg tissue in the vehicle group vs 2.2 ± 0.6 µg/mg tissue in the BMP7 group and in the thoracic aorta: 71 ± 27 µg/mg tissue in the vehicle group vs 54 ± 18 µg/mg tissue in the BMP7 group. Likewise, normalization of the uremic environment by aorta transplantation had no effect on the Ca-content of the calcified aorta: 16.3 ± 0.6 µg/mg tissue pre-transplantation vs 15.9 ± 2.3 µg/mg tissue post-transplantation. Aortic expression of genes directly linked to extracellular matrix calcification was not affected by BMP7 treatment, which hypothetically might explain persistent high Ca-content in established vascular calcification. The present results highlight the importance of preventing the development of vascular calcification in chronic kidney disease. Once established, vascular calcification persists even in the setting when hyperphosphatemia or the uremic milieu is abolished.


Subject(s)
Bone Morphogenetic Protein 7/pharmacology , Gene Expression Regulation/drug effects , Uremia/drug therapy , Vascular Calcification/drug therapy , Animals , Aorta/drug effects , Aorta/metabolism , Bone Morphogenetic Protein 7/therapeutic use , Chronic Disease , Fibrosis , Male , Phosphates/blood , Rats , Real-Time Polymerase Chain Reaction , Uremia/genetics , X-Ray Microtomography
2.
Am J Physiol Renal Physiol ; 314(5): F753-F762, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29187373

ABSTRACT

In a new paradigm of etiology related to chronic kidney disease-mineral and bone disorder (CKD-MBD), kidney injury may cause induction of factors in the injured kidney that are released into the circulation and thereby initiate and maintain renal fibrosis and CKD-MBD. Klotho is believed to ameliorate renal fibrosis and CKD-MBD, while activin A might have detrimental effects. The unilateral ureter obstruction (UUO) model is used here to examine this concept by investigating early changes related to renal fibrosis in the obstructed kidney, untouched contralateral kidney, and vasculature which might be affected by secreted factors from the obstructed kidney, and comparing with unilateral nephrectomized controls (UNX). Obstructed kidneys showed early Klotho gene and protein depletion, whereas plasma Klotho increased in both UUO and UNX rats, indicating an altered metabolism of Klotho. Contralateral kidneys had no compensatory upregulation of Klotho and maintained normal expression of the examined fibrosis-related genes, as did remnant UNX kidneys. UUO caused upregulation of transforming growth factor-ß and induction of periostin and activin A in obstructed kidneys without changes in the contralateral kidneys. Plasma activin A doubled in UUO rats after 10 days while no changes were seen in UNX rats, suggesting secretion of activin A from the obstructed kidney with potentially systemic effects on CKD-MBD. As such, increased aortic sclerostin was observed in UUO rats compared with UNX and normal controls. The present results are in line with the new paradigm and show very early vascular effects of unilateral kidney fibrosis, supporting the existence of a new kidney-vasculature axis.


Subject(s)
Acute Kidney Injury/blood , Chronic Kidney Disease-Mineral and Bone Disorder/blood , Glucuronidase/blood , Inhibin-beta Subunits/blood , Kidney/metabolism , Ureteral Obstruction/blood , Acute Kidney Injury/pathology , Acute Kidney Injury/physiopathology , Animals , Aorta/metabolism , Biomarkers/blood , Bone Morphogenetic Proteins/genetics , Bone Morphogenetic Proteins/metabolism , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/pathology , Chronic Kidney Disease-Mineral and Bone Disorder/physiopathology , Disease Models, Animal , Fibrosis , Gene Expression Regulation , Genetic Markers/genetics , Glucuronidase/genetics , Inhibin-beta Subunits/genetics , Kidney/pathology , Kidney/physiopathology , Klotho Proteins , Male , Rats, Wistar , Signal Transduction , Time Factors , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolism , Ureteral Obstruction/pathology , Ureteral Obstruction/physiopathology
3.
PLoS One ; 12(9): e0184992, 2017.
Article in English | MEDLINE | ID: mdl-28931076

ABSTRACT

Ghrelin is a peptide hormone produced mainly in the gastrointestinal tract known to regulate several physiological functions including gut motility, adipose tissue accumulation and hunger sensation leading to increased bodyweight. Studies have found a correlation between the plasma levels of thyroid hormones and ghrelin, but an effect of ghrelin on the human thyroid has never been investigated even though ghrelin receptors are present in the thyroid. The present study shows a ghrelin-induced decrease in the thyroid-stimulating hormone (TSH)-induced production of thyroglobulin and mRNA expression of thyroperoxidase in a primary culture of human thyroid cells obtained from paranodular tissue. Accordingly, a trend was noted for an inhibition of TSH-stimulated expression of the sodium-iodine symporter and the TSH-receptor. Thus, this study suggests an effect of ghrelin on human thyrocytes and thereby emphasizes the relevance of examining whether ghrelin also influences the metabolic homeostasis through altered thyroid hormone production.


Subject(s)
Cell Differentiation/drug effects , Ghrelin/pharmacology , Thyroid Gland/cytology , Thyrotropin/pharmacology , Cells, Cultured , Humans , Receptors, Ghrelin/metabolism , Receptors, Thyrotropin/metabolism , Thyroglobulin/metabolism , Thyroid Gland/drug effects , Thyroid Gland/metabolism
4.
PLoS One ; 12(6): e0179858, 2017.
Article in English | MEDLINE | ID: mdl-28644858

ABSTRACT

BACKGROUND: Normal thyroid function is essential for general growth and metabolism, but can be affected by endocrine disrupting chemicals (EDCs). Polybrominated diphenyl ethers (PBDEs) have been used worldwide to reduce flammability in different materials and are suspected to be EDCs. The production of the commercial Penta- and OctaBDE mixtures is banned, but DecaBDEs and existing products may leak PBDEs into the environment. Our aim was to investigate the effect of the PentaBDE mixture DE-71 on human thyroid cells in vitro. MATERIALS AND METHODS: Primary human thyroid cells were obtained as paraadenomatous tissue and cultured in monolayers. The influence of DE-71 on cyclic adenosine monophosphate (cAMP) and thyroglobulin (Tg) production was examined in the culture medium by competitive radioimmunoassay and enzyme-linked immunosorbent assay, respectively. Real-time quantitative PCR analysis of thyroid-specific genes was performed on the exposed cell cultures. PBDE concentrations were determined in cellular and supernatant fractions of the cultures. RESULTS: DE-71 inhibited Tg-release from TSH-stimulated thyrocytes. At 50 mg/L DE-71, mean Tg production was reduced by 71.9% (range: 8.5-98.7%), and cAMP by 95.1% (range: 91.5-98.8%) compared to controls). Expression of mRNA encoding Tg, TPO and TSHr were significantly inhibited (p<0.0001, p = 0.0079, and p = 0.0002, respectively). The majority of DE-71 added was found in the cell fraction. No cytotoxicity was found. CONCLUSIONS: DE-71 inhibited differentiated thyroid cell functions in a two phase response manner and a concentration-dependent inhibition of Tg and cAMP production, respectively, as well as expression of mRNA encoding Tg, TPO and TSHr. Our findings suggest an inhibiting effect of PBDEs on thyroid cells.


Subject(s)
Endocrine Disruptors/pharmacology , Flame Retardants/pharmacology , Halogenated Diphenyl Ethers/pharmacology , Thyroid Gland/drug effects , Adenoma/surgery , Cells, Cultured , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Enzyme-Linked Immunosorbent Assay , Humans , RNA, Messenger/metabolism , Radioimmunoassay , Real-Time Polymerase Chain Reaction , Thyroglobulin/metabolism , Thyroid Gland/metabolism , Thyroid Neoplasms/surgery , Thyroidectomy
5.
Kidney Int ; 92(1): 165-178, 2017 07.
Article in English | MEDLINE | ID: mdl-28341272

ABSTRACT

Fibroblast growth factor 23 (FGF23) secreted by osteocytes is a circulating factor essential for phosphate homeostasis. High plasma FGF23 levels are associated with cardiovascular complications and mortality. Increases of plasma FGF23 in uremia antedate high levels of phosphate, suggesting a disrupted feedback regulatory loop or an extra-skeletal source of this phosphatonin. Since induction of FGF23 expression in injured organs has been reported we decided to examine the regulation of FGF23 gene and protein expressions in the kidney and whether kidney-derived FGF23 contributes to the high plasma levels of FGF23 in uremia. FGF23 mRNA was not detected in normal kidneys, but was clearly demonstrated in injured kidneys, already after four hours in obstructive nephropathy and at 8 weeks in the remnant kidney of 5/6 nephrectomized rats. No renal extraction was found in uremic rats in contrast to normal rats. Removal of the remnant kidney had no effect on plasma FGF23 levels. Well-known regulators of FGF23 expression in bone, such as parathyroid hormone, calcitriol, and inhibition of the FGF receptor by PD173074, had no impact on kidney expression of FGF23. Thus, the only direct contribution of the injured kidney to circulating FGF23 levels in uremia appears to be reduced renal extraction of bone-derived FGF23. Kidney-derived FGF23 does not generate high plasma FGF23 levels in uremia and is regulated differently than the corresponding regulation of FGF23 gene expression in bone.


Subject(s)
Fibroblast Growth Factors/blood , Fibroblasts/metabolism , Kidney/metabolism , Renal Insufficiency, Chronic/blood , Uremia/blood , Animals , Biomarkers/blood , Bone and Bones/metabolism , Disease Models, Animal , Fibroblast Growth Factors/genetics , Fibrosis , Kidney/pathology , Kidney/physiopathology , Male , Parathyroid Hormone/blood , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats, Wistar , Receptors, Fibroblast Growth Factor/metabolism , Renal Insufficiency, Chronic/genetics , Renal Insufficiency, Chronic/physiopathology , Time Factors , Up-Regulation , Uremia/genetics , Uremia/physiopathology
6.
PLoS One ; 11(3): e0151192, 2016.
Article in English | MEDLINE | ID: mdl-26985823

ABSTRACT

Phthalates are plasticisers added to a wide variety of products, resulting in measurable exposure of humans. They are suspected to disrupt the thyroid axis as epidemiological studies suggest an influence on the peripheral thyroid hormone concentration. The mechanism is still unknown as only few in vitro studies within this area exist. The aim of the present study was to investigate the influence of three phthalate diesters (di-ethyl phthalate, di-n-butyl phthalate (DnBP), di-(2-ethylhexyl) phthalate (DEHP)) and two monoesters (mono-n-butyl phthalate and mono-(2-ethylhexyl) phthalate (MEHP)) on the differentiated function of primary human thyroid cell cultures. Also, the kinetics of phthalate metabolism were investigated. DEHP and its monoester, MEHP, both had an inhibitory influence on 3'-5'-cyclic adenosine monophosphate secretion from the cells, and MEHP also on thyroglobulin (Tg) secretion from the cells. Results of the lactate dehydrogenase-measurements indicated that the MEHP-mediated influence was caused by cell death. No influence on gene expression of thyroid specific genes (Tg, thyroid peroxidase, sodium iodine symporter and thyroid stimulating hormone receptor) by any of the investigated diesters could be demonstrated. All phthalate diesters were metabolised to the respective monoester, however with a fall in efficiency for high concentrations of the larger diesters DnBP and DEHP. In conclusion, human thyroid cells were able to metabolise phthalates but this phthalate-exposure did not appear to substantially influence selected functions of these cells.


Subject(s)
Dibutyl Phthalate/metabolism , Diethylhexyl Phthalate/metabolism , Phthalic Acids/metabolism , Plasticizers/metabolism , Thyroid Gland/drug effects , Thyroid Gland/metabolism , Cells, Cultured , Cyclic AMP/metabolism , Dibutyl Phthalate/toxicity , Diethylhexyl Phthalate/toxicity , Humans , Phthalic Acids/toxicity , Plasticizers/toxicity , Thyroglobulin/metabolism , Thyroid Gland/cytology
7.
Am J Physiol Renal Physiol ; 310(6): F477-91, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26739890

ABSTRACT

The development of vascular calcification (VC) in chronic uremia (CU) is a tightly regulated process controlled by factors promoting and inhibiting mineralization. Next-generation high-throughput RNA sequencing (RNA-seq) is a powerful and sensitive tool for quantitative gene expression profiling and the detection of differentially expressed genes. In the present study, we, for the first time, used RNA-seq to examine rat aorta transcriptomes from CU rats compared with control rats. Severe VC was induced in CU rats, which lead to extensive changes in the transcriptional profile. Among the 10,153 genes with an expression level of >1 reads/kilobase transcript/million mapped reads, 2,663 genes were differentially expressed with 47% upregulated genes and 53% downregulated genes in uremic rats. Significantly deregulated genes were enriched for ontologies related to the extracellular matrix, response to wounding, organic substance, and ossification. The individually affected genes were of relevance to osteogenic transformation, tissue calcification, and Wnt modulation. Downregulation of the Klotho gene in uremia is believed to be involved in the development of VC, but it is debated whether the effect is caused by circulating Klotho only or if Klotho is produced locally in the vasculature. We found that Klotho was neither expressed in the normal aorta nor calcified aorta by RNA-seq. In conclusion, we demonstrated extensive changes in the transcriptional profile of the uremic calcified aorta, which were consistent with a shift in phenotype from vascular tissue toward an osteochondrocytic transcriptome profile. Moreover, neither the normal vasculature nor calcified vasculature in CU expresses Klotho.


Subject(s)
Aorta, Abdominal/metabolism , Uremia/metabolism , Vascular Calcification/metabolism , Animals , Chronic Disease , Gene Expression Profiling , Gene Ontology , Glucuronidase/metabolism , Klotho Proteins , Male , Rats , Sequence Analysis, RNA , Uremia/complications , Vascular Calcification/etiology
8.
Kidney Int ; 88(6): 1304-1313, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26221757

ABSTRACT

High circulating levels of fibroblast growth factor 23 (FGF23) have been demonstrated in kidney failure, but mechanisms of this are not well understood. Here we examined the impact of the kidney on the early regulation of intact FGF23 in acute uremia as induced by bilateral or unilateral nephrectomy (BNX and UNX, respectively) in the rat. BNX induced a significant increase in plasma intact FGF23 levels from 112 to 267 pg/ml within 15 min, which remained stable thereafter. UNX generated intact FGF23 levels between that seen in BNX and sham-operated rats. The intact to C-terminal FGF23 ratio was significantly increased in BNX rats. The rapid rise in FGF23 after BNX was independent of parathyroid hormone or FGF receptor signaling. No evidence of early stimulation of FGF23 gene expression in the bone was found. Furthermore, acute severe hyperphosphatemia or hypercalcemia had no impact on intact FGF23 levels in normal and BNX rats. The half-life of exogenous recombinant human FGF23 was significantly prolonged from 4.4 to 11.8 min in BNX rats. Measurements of plasma FGF23 in the renal artery and renal vein demonstrated a significant renal extraction. Thus the kidney is important in FGF23 homeostasis by regulation of its plasma level and metabolism.

9.
Calcif Tissue Int ; 95(1): 46-53, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24801007

ABSTRACT

The regulation of fibroblast growth factor 23 (FGF23) synthesis and secretion is still incompletely understood. FGF23 is an important regulator of renal phosphate excretion and has regulatory effects on the calciotropic hormones calcitriol and parathyroid hormone (PTH). Calcium (Ca) and phosphate homeostasis are closely interrelated, and it is therefore likely that Ca is involved in FGF23 regulation. It has recently been reported that dietary Ca influenced FGF23 levels, with high Ca increasing FGF23. The mechanism remains to be clarified. It remains unknown whether acute changes in plasma Ca influence FGF23 levels and whether a close relationship, similar that known for Ca and PTH, exists between Ca and FGF23. Thus, the aim of the present study was to examine whether acute hypercalcemia and hypocalcemia regulate FGF23 levels in the rat. Acute hypercalcemia was induced by an intravenous Ca infusion and hypocalcemia by infusion of ethylene glycol tetraacetic acid (EGTA) in normal and acutely parathyroidectomized rats. Intact plasma FGF23 and intact plasma PTH and plasma Ca(2+) and phosphate were measured. Acute hypercalcemia and hypocalcemia resulted as expected in adequate PTH secretory responses. Plasma FGF23 levels remained stable at all plasma Ca(2+) levels; acute parathyroidectomy did not affect FGF23 secretion. In conclusion, Ca is not a regulator of acute changes in FGF23 secretion.


Subject(s)
Calcium/blood , Fibroblast Growth Factors/blood , Homeostasis/physiology , Animals , Enzyme-Linked Immunosorbent Assay , Hypercalcemia/blood , Hypocalcemia/blood , Male , Parathyroid Hormone/blood , Parathyroidectomy , Rats , Rats, Wistar
10.
BMC Nephrol ; 14: 281, 2013 Dec 27.
Article in English | MEDLINE | ID: mdl-24373521

ABSTRACT

BACKGROUND: High iron load might have a number of toxic effects in the organism. Recently intravenous (iv) iron has been proposed to induce elevation of fibroblast growth factor 23 (FGF23), hypophosphatemia and osteomalacia in iron deficient subjects. High levels of FGF23 are associated with increased mortality in the chronic kidney disease (CKD) population. CKD patients are often treated with iv iron therapy in order to maintain iron stores and erythropoietin responsiveness, also in the case of not being iron depleted. Therefore, the effect of a single high iv dose of two different iron preparations, iron isomaltoside 1000 (IIM) and ferric carboxymaltose (FCM), on plasma levels of FGF23 and phosphate was examined in normal and uremic iron repleted rats. METHODS: Iron was administered iv as a single high dose of 80 mg/kg bodyweight and the effects on plasma levels of iFGF23, phosphate, Ca2+, PTH, transferrin, ferritin and iron were examined in short and long term experiments (n = 99). Blood samples were obtained at time 0, 30, 60, 180 minutes, 24 and 48 hours and in a separate study after 1 week. Uremia was induced by 5/6-nephrectomy. RESULTS: Nephrectomized rats had significant uremia, hyperparathyroidism and elevated FGF23. Iron administration resulted in significant increases in plasma ferritin levels. No significant differences were seen in plasma levels of iFGF23, phosphate and PTH between the experimental groups at any time point within 48 hours or at 1 week after infusion of the iron compounds compared to vehicle. CONCLUSIONS: In non-iron depleted normal and uremic rats a single high dose of either of two intravenous iron preparations, iron isomaltoside 1000, and ferric carboxymaltose, had no effect on plasma levels of iFGF23 and phosphate for up to seven days.


Subject(s)
Fibroblast Growth Factors/blood , Iron/administration & dosage , Phosphates/blood , Uremia/blood , Uremia/drug therapy , Animals , Homeostasis/drug effects , Injections, Intravenous , Male , Rats , Rats, Wistar , Treatment Outcome , Uremia/diagnosis
11.
Scand J Clin Lab Invest ; 73(2): 107-16, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23281842

ABSTRACT

BACKGROUND: Focus on non-classical effects and possible less side effects of treatment with nutritional vitamin D, raises the expectation of possible benefits from treating chronic kidney disease (CKD) patients with ergocalciferol (vitamin D2). Treatment with 1,25(OH)2 vitamin D (calcitriol) induces elevated fibroblast growth factor 23 (FGF23), while epidemiological studies have found positive effects of nutritional and 25(OH)vitamin D on mortality in CKD. Disturbed mineral homeostasis in CKD is correlated to adverse outcome and cardiovascular mortality. The objective was to examine the possible effects of treatment with high doses of ergocalciferol on parameters of mineral homeostasis in predialysis CKD patients. METHODS: A total of 43 adult patients with CKD stage 4-5, not receiving vitamin D supplementation, were studied, and allocated by simple randomization to either an intervention (n = 26) or a control group (n = 17). The intervention group received ergocalciferol, 50.000 IU/week for 6 weeks. Plasma FGF23, creatinine, parathyroid hormone (PTH), phosphate and ionized calcium were obtained at baseline and after the 6 weeks. RESULTS: The intervention group had a significant increase in 25(OH)D2 concentration from < 10 to 90 ± 4 nmol/L, while 1,25(OH)2D (62 ± 6 at baseline and 67 ± 6 pmol/L at 6 weeks) remained stable. No changes were seen in the circulating vitamin D concentrations in the control group. After the 6 weeks of treatment no significant changes were seen in concentration of creatinine, phosphate, ionized calcium, PTH and FGF23 remained stable. CONCLUSION: No harmful effects of short-term treatment with high-dose ergocalciferol were observed on markers of mineral homeostasis and FGF23 in CKD patients stage 4-5.


Subject(s)
Bone and Bones/metabolism , Ergocalciferols/therapeutic use , Renal Insufficiency, Chronic/drug therapy , Vitamins/therapeutic use , Adult , Bone and Bones/drug effects , Calcium/blood , Creatinine/blood , Ergocalciferols/pharmacokinetics , Female , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Homeostasis , Humans , Male , Parathyroid Hormone/blood , Phosphates/blood , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/mortality , Renal Insufficiency, Chronic/pathology , Treatment Outcome , Vitamins/pharmacokinetics
12.
Int J Nephrol ; 2012: 123576, 2012.
Article in English | MEDLINE | ID: mdl-23094155

ABSTRACT

Secondary hyperparathyroidism (s-HPT) in uremia is characterized by decreased expression in the parathyroids of calcium sensing (CaR) and vitamin D receptors (VDR). Parathyroid hormone (PTH) is normalized despite low levels of CaR and VDR after experimental reversal of uremia. The expression of CaR in parathyroid cultures decreases rapidly. Methylation of promoter regions is often detected during epigenetic downregulation of gene expression. Therefore, using an experimental rat model, we examined changes in methylation levels of parathyroid CaR and VDR promoters in vivo and in vitro. Methods. Uremia was induced by 5/6 nephrectomy. Melting temperature profiling of CaR and VDR PCR products after bisulfite treatment of genomic DNA from rat parathyroids was performed. Real-time PCR measured expression of PTH, CaR, VDR, and klotho genes in vitro. Results. Parathyroids from uremic rats had similar low levels of methylation in vivo and in vitro. In culture, a significant downregulation of CaR, VDR, and klotho within two hours of incubation was observed, while housekeeping genes remained stable for 24 hours. Conclusion. In uremic s-HPT and in vitro, no overall changes in methylation levels in the promoter regions of parathyroid CaR and VDR genes were found. Thus, epigenetic methylation of these promoters does not explain decreased parathyroid expression of CaR and VDR genes in uremic s-HPT.

13.
Eur J Pharmacol ; 660(2-3): 351-7, 2011 Jun 25.
Article in English | MEDLINE | ID: mdl-21515256

ABSTRACT

The effect of brain-derived neurotrophic factor (BDNF) on activity-regulated cytoskeleton-associated protein (Arc) mRNA levels in primary neuronal cultures of rat frontal cortex was characterized pharmacologically and compared to the effect on expression of c-fos, bdnf, neuritin, cox-2 as examples of other immediate early genes. BDNF induced a very strong increase (around 100 fold) in Arc mRNA and the maximal effect seen at 25 ng/ml. The effect was dose-dependent with EC50 around 1.6 ng/ml. The time profile revealed a significant effect after 25 min. BDNF also increased levels of c-Fos, neuritin and BDNF mRNA, but not COX-2 mRNA. The pharmacological profile of NMDA and AMPA-induced arc gene expression in frontal cortical neurons was compared to BDNF. NMDA and AMPA increased Arc mRNA but their maximal effect did not exceed 20-fold. The effect of AMPA was completely blocked by the NMDA receptor antagonist MK-801. Further, the relative amount of Arc mRNA compared to c-Fos mRNA was higher for BDNF, equal for NMDA and lower for AMPA. These results demonstrate BDNF to be a highly potent and efficient inducer of arc gene expression in vitro, emphasizing the role of this growth factor in synaptic plasticity in the frontal cortex.


Subject(s)
Brain-Derived Neurotrophic Factor/pharmacology , Cytoskeletal Proteins/genetics , Frontal Lobe/cytology , Gene Expression Regulation/drug effects , N-Methylaspartate/pharmacology , Nerve Tissue Proteins/genetics , Neurons/drug effects , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology , Animals , Dose-Response Relationship, Drug , Female , Humans , Neurons/metabolism , Pregnancy , Proto-Oncogene Proteins c-fos/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, AMPA/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Time
14.
Kidney Int ; 79(7): 742-8, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21209610

ABSTRACT

The involvement of sodium/potassium-ATPase in regulating parathyroid hormone (PTH) secretion is inferred from in vitro studies. Recently, the α-klotho-dependent rapid recruitment of this ATPase to the parathyroid cell plasma membrane in response to low extracellular calcium ion was suggested to be linked to increased hormone secretion. In this study, we used an in vivo rat model to determine the importance of sodium/potassium-ATPase in PTH secretion. Glands were exposed and treated in situ with vehicle or ouabain, a specific inhibitor of sodium/potassium-ATPase. PTH secretion was significantly increased in response to ethylene glycol tetraacetic acid-induced acute hypocalcemia and to the same extent in both vehicle and ouabain groups. The glands were removed, and inhibition of the ATPase was measured by (86)rubidium uptake, which was found to be significantly decreased in ouabain-treated parathyroid glands, indicating inhibition of the ATPase. As ouabain induced systemic hyperkalemia, the effect of high potassium on hormone secretion was also examined but was found to have no effect. Thus, inhibition of the parathyroid gland sodium/potassium-ATPase activity in vivo had no effect on the secretory response to acute hypocalcemia. Hence, the suggested importance of this ATPase in the regulation of PTH secretion could not be confirmed in this in vivo model.


Subject(s)
Hypocalcemia/physiopathology , Parathyroid Glands/metabolism , Parathyroid Hormone/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism , Animals , Calcium/blood , Disease Models, Animal , Egtazic Acid , Enzyme Inhibitors/pharmacology , Hypocalcemia/chemically induced , Hypocalcemia/enzymology , Male , Ouabain/pharmacology , Parathyroid Glands/drug effects , Parathyroid Glands/enzymology , Parathyroid Hormone/blood , Potassium/blood , Rats , Rubidium Radioisotopes , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Time Factors
15.
Kidney Int ; 78(11): 1119-27, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20631679

ABSTRACT

Klotho is a protein of significant importance for mineral homeostasis. It helps to increase parathyroid hormone (PTH) secretion and in the trafficking of Na+/K+-ATPase to the cell membrane; however, it is also a cofactor for fibroblast growth factor (FGF)-23 to interact with its receptor, FGFR1 IIIC, resulting in decreased PTH secretion. Studies on the regulation of parathyroid klotho expression in uremia have provided varying results. To help resolve this, we measured klotho expression in the parathyroid and its response to severe uremia, hyperphosphatemia, and calcitriol treatment in the 5/6 nephrectomy rat model of secondary hyperparathyroidism. Parathyroid klotho gene expression and protein were significantly increased in severely uremic hyperphosphatemic rats, but not affected by moderate uremia and normal serum phosphorus. Calcitriol suppressed klotho gene and protein expression in severe secondary hyperparathyroidism, despite a further increase in plasma phosphate. Both FGFR1 IIIC and Na+/K+-ATPase gene expression were significantly elevated in severe secondary hyperparathyroidism. Parathyroid gland klotho expression and the plasma calcium ion concentration were inversely correlated. Thus, our study suggests that klotho may act as a positive regulator of PTH expression and secretion in secondary hyperparathyroidism.


Subject(s)
Glucuronidase/metabolism , Hyperparathyroidism, Secondary/metabolism , Hyperphosphatemia/metabolism , Parathyroid Glands/metabolism , Uremia/metabolism , Animals , Calcitriol/pharmacology , Calcium/blood , Disease Models, Animal , Fibroblast Growth Factors/metabolism , Glucuronidase/genetics , Hyperparathyroidism, Secondary/drug therapy , Hyperparathyroidism, Secondary/etiology , Hyperparathyroidism, Secondary/genetics , Hyperphosphatemia/etiology , Hyperphosphatemia/genetics , Klotho Proteins , Male , Nephrectomy , Parathyroid Glands/drug effects , Parathyroid Hormone/blood , Parathyroid Hormone/genetics , Phosphorus/blood , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptor, Fibroblast Growth Factor, Type 1/genetics , Receptors, Calcitriol/genetics , Receptors, Calcium-Sensing/genetics , Sodium-Potassium-Exchanging ATPase/genetics , Up-Regulation , Uremia/drug therapy , Uremia/etiology , Uremia/genetics
16.
Heart Rhythm ; 5(3): 427-35, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18313602

ABSTRACT

BACKGROUND: Atrial fibrillation (AF) is the most common clinical arrhythmia and a major cause of cardiovascular morbidity and mortality. Among the gene defects previously associated with AF is a gain of function of the slowly activating delayed rectifier potassium current IKs, secondary to mutations in KCNQ1. Coexpression of KCNE5, the gene encoding the MiRP4 beta-subunit, has been shown to reduce IKs. OBJECTIVE: The purpose of this study was to test the hypothesis that mutations in KCNE5 are associated with AF in a large cohort of patients with AF. METHODS: One-hundred fifty-eight patients with AF were screened for mutations in the coding region of KCNE5. RESULTS: A missense mutation involving substitution of a phenylalanine for leucine at position 65 (L65F) was identified in one patient. This patient did not have a history of familial AF, and neither KCNQ1 nor KCNE2 mutations were found. Transient transfection of Chinese hamster ovary (CHO) cells expressing IKs(KCNQ1+KCNE1) with KCNE5 suppressed the developing and tail currents of IKs in a concentration-dependent manner. Transient transfection with KCNE5-L65F failed to suppress IKs, yielding a current indistinguishable from that recorded in the absence of KCNE5. Developing currents recorded during a test pulse to +60 mV and tail currents recorded upon repolarization to -40 mV both showed a significant concentration-dependent gain of function in IKs with expression of KCNE5-L65F vs KCNE5-WT. CONCLUSION: The results of this study suggest that a missense mutation in KCNE5 may be associated with nonfamilial or acquired forms of AF. The arrhythmogenic mechanism most likely is a gain of function of IKs.


Subject(s)
Atrial Fibrillation/genetics , Mutation, Missense , Potassium Channels, Voltage-Gated/genetics , Adult , Aged , Aged, 80 and over , Analysis of Variance , Atrial Fibrillation/physiopathology , Denmark , Electrocardiography , Electrophysiologic Techniques, Cardiac , Female , Humans , Male , Middle Aged
17.
Circ Arrhythm Electrophysiol ; 1(3): 209-18, 2008 Aug.
Article in English | MEDLINE | ID: mdl-19122847

ABSTRACT

INTRODUCTION: The Brugada Syndrome (BrS), an inherited syndrome associated with a high incidence of sudden cardiac arrest, has been linked to mutations in four different genes leading to a loss of function in sodium and calcium channel activity. Although the transient outward current (I(to)) is thought to play a prominent role in the expression of the syndrome, mutations in I(to)-related genes have not been identified as yet. METHODS AND RESULTS: One hundred and five probands with BrS were screened for ion channel gene mutations using single strand conformation polymorphism (SSCP) electrophoresis and direct sequencing. A missense mutation (R99H) in KCNE3 (MiRP2) was detected in one proband. The R99H mutation was found 4/4 phenotype positive and 0/3 phenotype-negative family members. Chinese hamster ovary (CHO)-K1 cells were co-transfected using wild-type (WT) or mutant KCNE3 and either WT KCND3 or KCNQ1. Whole-cell patch clamp studies were performed after 48 hours. Interactions between Kv4.3 and KCNE3 were analyzed in co-immunoprecipitation experiments in human atrial samples. Co-transfection of R99H-KCNE3 with KCNQ1 produced no alteration in current magnitude or kinetics. However, co-transfection of R99H KCNE3 with KCND3 resulted in a significant increase in the I(to) intensity compared to WT KCNE3+KCND3. Using tissues isolated from left atrial appendages of human hearts, we also demonstrate that K(v)4.3 and KCNE3 can be co-immunoprecipitated. CONCLUSIONS: These results provide definitive evidence for a functional role of KCNE3 in the modulation of I(to) in the human heart and suggest that mutations in KCNE3 can underlie the development of BrS.


Subject(s)
Brugada Syndrome/genetics , DNA/genetics , Genetic Predisposition to Disease , Mutation, Missense , Potassium Channels, Voltage-Gated/genetics , Action Potentials , Adolescent , Adult , Aged , Brugada Syndrome/metabolism , Brugada Syndrome/physiopathology , Cells, Cultured , Child , DNA Mutational Analysis , Female , Follow-Up Studies , Humans , Immunoprecipitation , Male , Middle Aged , Myocardium/metabolism , Myocardium/pathology , Patch-Clamp Techniques , Pedigree , Potassium Channels, Voltage-Gated/metabolism , Young Adult
18.
Biochem Biophys Res Commun ; 354(3): 776-82, 2007 Mar 16.
Article in English | MEDLINE | ID: mdl-17266934

ABSTRACT

Mutations in one of the ion channels shaping the cardiac action potential can lead to action potential prolongation. However, only in a minority of cardiac arrest cases mutations in the known arrhythmia-related genes can be identified. In two patients with arrhythmia and cardiac arrest, we identified the point mutations P91L and E33V in the KCNA5 gene encoding the Kv1.5 potassium channel that has not previously been associated with arrhythmia. We functionally characterized the mutations in HEK293 cells. The mutated channels behaved similarly to the wild-type with respect to biophysical characteristics and drug sensitivity. Both patients also carried a D85N polymorphism in KCNE1, which was neither found to influence the Kv1.5 nor the Kv7.1 channel activity. We conclude that although the two N-terminal Kv1.5 mutations did not show any apparent electrophysiological phenotype, it is possible that they may influence other cellular mechanisms responsible for proper electrical behaviour of native cardiomyocytes.


Subject(s)
Heart Arrest/genetics , Kv1.5 Potassium Channel/genetics , Mutation/genetics , Cells, Cultured , Child , Cloning, Molecular , Electrophysiology , Female , Heart Arrest/pathology , Humans , Male , Middle Aged , Myocytes, Cardiac/pathology , Phenotype , Potassium Channels, Voltage-Gated/genetics , Time Factors
19.
Heart Rhythm ; 2(11): 1238-49, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16253915

ABSTRACT

BACKGROUND: Long QT syndrome (LQTS) is a cardiovascular disorder characterized by prolonged QTc time, syncope, or sudden death caused by torsades de pointes and ventricular fibrillation. We investigated the clinical and electrophysiologic phenotype of individual mutations and the compound mutations in a family in which different genotypes could be found. OBJECTIVES: The purpose of this study was to determine the impact of genotype-based diagnostic assessment in LQTS. METHODS: We used cascade screening and functional analyses to investigate the phenotype in a family with LQTS. The contributions of the compound mutations in the KCNQ1 and KCNH2 genes (KCNQ1 R591H, KCNH2 R328C) were analyzed by heterologous expression in Xenopus laevis oocytes using two-electrode voltage clamp and by confocal imaging. RESULTS: KCNH2 R328C did not show any functional phenotype whereas KCNQ1 R591H resulted in severe reduction of current. Neither wild-type nor mutant channels affected each other functionally in coexpression experiments. Therefore, a direct interaction between KCNQ1 and KCNH2 was ruled out under these conditions. CONCLUSION: Assessment of novel mutational findings in LQTS should include accurate genetic and functional analysis. Notably, appropriate studies are needed if two or more mutations in different genes are present in one proband. Our findings prompt reconsideration of the impact of compound mutations in LQTS families and reinforce the need for thorough functional evaluation of novel ion channel mutations before assignment of pathogenic status.


Subject(s)
DNA/genetics , Ether-A-Go-Go Potassium Channels/genetics , KCNQ1 Potassium Channel/genetics , Long QT Syndrome/genetics , Mutation, Missense , Alleles , ERG1 Potassium Channel , Electrophysiology , Ether-A-Go-Go Potassium Channels/metabolism , Female , Genetic Predisposition to Disease , Genotype , Heart Rate/physiology , Humans , KCNQ1 Potassium Channel/metabolism , Long QT Syndrome/metabolism , Long QT Syndrome/physiopathology , Male , Middle Aged , Pedigree , Phenotype , Polymerase Chain Reaction
20.
Ugeskr Laeger ; 167(33): 3060-1, 2005 Aug 15.
Article in Danish | MEDLINE | ID: mdl-16109254

ABSTRACT

Brugada syndrome is a primary electrical disease involving a wide spectrum of phenotypes. The hallmark of Brugada syndrome is the ST elevation in leads V1 to V3. We present three cases of Brugada syndrome. The first patient was diagnosed via routine ECG and a programmed electric stimulation. The second patient was mistakenly diagnosed as having a right coronary occlusion. The last patient had been resuscitated before admittance and received an implantable cardioverter-defibrillator. Treatment of patients with Brugada syndrome is limited by the lack of reliable indicators of risk.


Subject(s)
Tachycardia, Ventricular/diagnosis , Ventricular Fibrillation/diagnosis , Adult , Diagnosis, Differential , Electrocardiography , Humans , Male , Middle Aged , Mutation , Risk Factors , Syndrome , Tachycardia, Ventricular/genetics , Tachycardia, Ventricular/physiopathology , Ventricular Fibrillation/genetics , Ventricular Fibrillation/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...